Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

e global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales. For more information please visit www.us.boehringer-ingelheim.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568105PR

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient exp
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... HORSHAM, Pa., Sept. 20, 2011 Verilogue, the ... upcoming presentations highlighting company initiatives, including CareCoach.com, the ... healthcare dialogue between patients, caregivers and their physicians. ... conferences in September: e-Patient Connections; ...
... Sept. 20, 2011 Reportlinker.com announces that a ... catalogue: Rheumatoid Arthritis Market Forecast ... The launch of novel oral drugs and reformulations ... across the seven major markets, rising from $12bn ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Rheumatoid Arthritis Market Forecast 2
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids ... are now being treated at Florida Hospital Tampa with the device that provides ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... La Mirada, CA (PRWEB) , ... July 31, ... ... in Southern California, has announced plans to release a newly redesigned website at ... easier navigation and enhanced user experience. , The redesign serves to provide ...
(Date:7/31/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... July 31, ... ... the 100th baby at Beaumont Hospital's Karmanos Center for Natural Birth . ... expectant mothers looking for a safe natural childbirth experience. With nurses and caregivers ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business ... oils from ingredients sourced all over the world, then manufactured into specific formulations ... have developed the highest-quality oils in the industry, which we are bringing to ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
... needed for quality, comprehensive portable and bedside ... allows you to see up to four ... touch screen allows easy navigation through menus ... temperature., ,Standard features include two channels ...
... all-in-one anesthesia monitor., ,The Cardiocap/5 ... for use in the operating room, ... PACU. The Cardiocap/5 offers full vital ... of oxygenation and circulation to advanced ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... for intermediate care., ,The S/5 FM is ... S/5 product line., ,The S/5 FM has ... to grow. The new Patient Side Module (PSM) ... up to 12-lead ECG, NIBP, motion-tolerant SpO 2 ...
Medicine Products: